Ionis Pharmaceuticals
From Infogalactic: the planetary knowledge core
(Redirected from Isis Pharmaceuticals)
 |
|
|
Formerly called
|
Isis Pharmaceuticals |
|---|---|
| Industry | Biotechnology |
| Headquarters | Carlsbad, United States |
| Products | Mipomersen, Alicaforsen |
| Website | www |
Ionis Pharmaceuticals (NASDAQ: IONS), known as Isis Pharmeceuticals until December 2015,[1][2] is a publicly traded pharmaceutical company based in Carlsbad, California, United States. It has a single cholesterol-reducing drug in the market and several compounds in the drug pipeline including IONIS-HTTRx, the first intrathecally administered huntingtin-lowering drug for Huntington's disease;[3] and nusinersen (IONIS-SMNRx), an intrathecally administered antisense oligonucleotide drug for spinal muscular atrophy.
The company was founded in 1989 by Stanley Crooke, a former GlaxoSmithKline head of research, with a view to commercialize antisense therapy.[4]
